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1  |  INTRODUCTION
Drug Discovery and Chemical Biology encompasses many 
techniques and many perspectives: It is a set of disciplines 
that has been exploited but could be exploited more. Vaccine 
development in particular is an area in which Drug Discovery 
and Chemical Biology is yet to play its part as fully as it 
should. In the last decade, following the crisis in confidence 
and failure in performance that gripped the Pharmaceutical 
Industry, the search for new income streams has seen inter 
alia a rise in biologic drugs, medical devices and vaccines, 
as potential part- saviours of the Industry. We have recently 
exemplified an immunoinformatics- based approach to the 
selection- based design of optimal prevalidated epitope en-
semble vaccines by demonstrating the reproducibility of this 
strategy by proposing a range of putative vaccines against 
hepatitis C,[1] influenza[2] and malaria.[3] We focus here on 
the further exemplification of this methodology by designing 
potential epitope- based polyvalent putative vaccine candi-
dates against the dengue virus.
Dengue virus (DENV) belongs to the genus Flavivirus, 
having four different serotypes (DENV- 1, DENV- 2, DENV- 3 
and DENV- 4), with 65% sequence conservation across all se-
rotypes.[4] DENV is transmitted to humans by female Aedes 
albopictus and Aedes aegypti peridomestic mosquitoes. 
A. aegypti is the more efficient vector. In the last decade, 
DENV has spread to areas between 30°N and 40°S of the 
equator, with cases of infection reported in over 128 coun-
tries.[5] Bhatt et al.[6] estimated about 390 million are infected 
with DENV annually; 96 million cases resulting in illness.
Only 25% of primary dengue infections are symptom-
atic. Serious complications are rare, due to the production 
Received: 11 April 2018 | Revised: 29 May 2018 | Accepted: 10 June 2018
DOI: 10.1111/cbdd.13357
R E S E A R C H  A R T I C L E
Selection- based design of in silico dengue epitope ensemble 
vaccines
David Murphy1 | Pedro Reche2  | Darren R. Flower1
1School of Life and Health Sciences, Aston 
University, Birmingham, UK
2Immunomedicine Group, Departamento 
de Inmunología, Facultad de 
Medicina, Universidad Complutense de 
Madrid, Madrid, Spain
Correspondence
Darren R. Flower, School of Life and 
Health Sciences, Aston University, Aston 
Triangle, Birmingham, B4 7ET, UK.
Email: d.r.flower@aston.ac.uk
Funding information
Aston University
Dengue virus affects approximately 130 countries. Twenty- five percentage of infec-
tions result in febrile, self- limiting illness; heterotypic infection results in potentially 
fatal dengue haemorrhagic fever or dengue shock syndrome. Only one vaccine is 
currently available. Its efficacy is very variable. Thus, to target dengue, we used an 
innovative immunoinformatics protocol to design a putative epitope ensemble vac-
cine by selecting an optimal set of highly conserved epitopes with experimentally 
verified immunogenicity. From 1597 CD4+ and MHC II epitopes, six MHC Class I 
epitopes (RAVHADMGYW, GPWHLGKLEM, GLYGNGVVTK, NMIIMDEAHF, 
KTWAYHGSY and WAYHGSYEV) and nine MHC Class II epitopes 
(LAKAIFKLTYQNKVV, GKIVGLYGNGVVTTS, AAIFMTATPPGSVEA, 
AAIFMTATPPGTADA, GKTVWFVPSIKAGND, KFWNTTIAVSMANIF, 
RAIWYMWLGARYLEF, VGTYGLNTFTNMEVQ and WTLMYFHRRDLRLAA) 
were selected; this candidate vaccine achieved a world population coverage of 
92.49%.
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of neutralizing antibodies (nAb), which prevent viral entry 
into dendritic cells (DCs), and IFN- γ and TNF- α pro- 
inflammatory cytokines.[7] Postinfection, memory B cells 
provide lifelong homotypic immunity. Symptoms are more 
severe during secondary heterotypic infection, resulting in 
dengue haemorrhagic fever (DHF).
DHF is characterized by acute capillary leakage, clinically 
significant thrombocytopenia and varying degrees of liver in-
jury.[8] Due to cross- reactivity and the low threshold needed 
for antigen stimulation, memory B cells from the primary in-
fection bind epitopes on different DENV serotype, but with 
lower avidity, reducing the humoral response. This muted 
immune response, accompanied by IFN- γ, TNF- α, IL- 2, 
IL- 4 and IL- 6 production, induce a so- called cytokine storm, 
resulting in widespread systemic inflammation and subse-
quent plasma leakage.[9] During secondary infection, produc-
tion of low- affinity antibodies abrogates viral neutralization. 
Resulting antibody–antigen complexes bind to FC receptors 
and are internalized faster than during primary infection.[4]
DENV is a 50- nm virion, spherical in shape, with a 
10.7 kb genome comprising single- stranded, positive- sense 
RNA. Its genome is transcribed as a single polyprotein, 
which is cleaved into three structural proteins (capsid (C), 
membrane (M) and envelope (E)) and seven nonstructural 
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). 
The envelope protein is involved in cellular attachment, cell 
entry, membrane fusion and host cell virion assembly.[4]
Once transmission, dengue infects immature dendritic 
cells. The envelope protein binds to the nonspecific recep-
tor DC- specific ICAM- 3 grabbing nonintegrin, enabling 
viral entry into the cell.[10] DENV then becomes internalized 
into vesicles, where the viral envelope fuses to endosomal 
membranes, with single- stranded DNA then released into the 
DC’s cytoplasm.[11]
Several dengue vaccines are in development. CYD- TDV 
is a live, attenuated, chimeric, tetravalent vaccine manufac-
tured by Sanofi Pasteur, marketed as Dengvaxia®. Based 
on the YFV 7D vaccine, CYD- TVD consists of four recom-
binant, tetravalent, chimeric vaccines. It has completed two 
Phase III clinical trials: CD14 (South- East Asia) and CD15 
(Latin America). The overall vaccine efficacy in CD14 was 
56.5% and 60.8% in CD15.[12] For individual serotypes, CYD- 
TDV showed variable efficacy in CD14: 50% for DENV- 1 and 
35% for DENV- 2, too low to ensure any immune protection, 
78.4% against DENV- 3 and 75.3% against DENV- 4. In CD15, 
CYD- TDV also varied in efficacy across serotypes: 77.7% 
for DENV- 4, 74% for DENV- 3, 50.3% for DENV- 1 and 42.3 
for DENV- 2. In a follow- up study, an unexplained increase in 
DHF/DSS was reported in children under nine in Asian and 
Latin American countries.[13] This may result from heterotypic 
infection by DENV- 2. As CYD- TDV has significantly lower 
efficacy for DENV- 2 compared to other serotypes, DENV- 2 
infection may have caused heterotypic Dengue infection.
“DENVax” from Takeda Vaccines Inc. is a chimeric vac-
cine comprising live, attenuated DENV- 2, combined with 
preM and E genes from DENV- 1, DENV- 3 and DENV- 4. 
It has completed a Phase II trial in Puerto Rico, Columbia, 
Singapore and Thailand, with no ADR reported, demonstrat-
ing the vaccine’s safety. Seropositivity for DENV- 1, DENV- 2 
and DENV- 3 was reported to be >95% but for DENV4 ranged 
from 72.7% to 100%.[12]
LAV Delta 30 developed by NAID/Butantan is a serotype- 
specific live, attenuated vaccine.[12] Phase I studies have shown 
its safety and immunogenicity. DEN1- 80E, a recombinant, enve-
lope glycoprotein subunit vaccine, is being developed by Merck 
and Hawaii Biotech Inc.[12,14] The vaccine has undergone an ini-
tial Phase I clinical trial and was found to be well- tolerated, im-
munogenic, with no ADR reported. Another tetravalent vaccine 
containing monovalent DNA, encoding the prM and E genes of 
the four DENV serotypes, using Vaxfectin® (Vical Inc.) as an 
adjuvant, has undergone Phase I clinical trial. A subsidiary vac-
cine, D1ME100 (a DENV- 1 vaccine construct) was also tested 
on healthy Flavivirus naïve adults over 5 months with either 1 
or 5 mg doses.[12,15] In this context, additional vaccines for den-
gue are sorely needed. An ideal epitope- based vaccine would 
focus on highly conserved immunogenic epitopes with wide 
coverage. Here, we use our evolving approach to the selection- 
based design of prevalidated vaccine candidates[1–3] to create a 
putative antidengue epitope ensemble vaccine.
2 |  METHODS AND MATERIALS
2.1 | Collection of MHC Class I and Class II 
epitopes
Experimentally verified CD8+ and CD4+ DENV epitopes 
were downloaded from IEDB (http://www.iedb.org).[16] 
CD8+ epitope search criteria were dengue virus (ID: 
12637)- specific CD8+ linear epitopes positive in T- cell 
assays, known to infect humans, and involved in any dis-
ease. CD4+ epitope search criteria were dengue virus 
(ID: 12637)- specific CD4+ linear epitopes positive in T- 
cell assays, known to infect humans, and involved in any 
disease.
2.2 | Retrieval, processing and generation of 
MSA from the dengue polyprotein
Protein sequences corresponding to the dengue genomic se-
quence were initially retrieved from UniProt (http://www.
uniprot.org)[17] and searched against the protein reference 
sequences (Refseq_protein) using BLASTp (https://blast.
ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins). A multiple se-
quence alignment (MSA) was generated from the top four 
related sequences.
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2.3 | Variability analysis of MSA and 
identification of conserved sequences
The MSA was analysed using the protein variability server 
(PVS) (http://imed.med.ucm.es/PVS/index.html), which 
quantifies and masks sequence variability, returning con-
served subsequences.[18] A threshold of 0.5 was used, return-
ing conserved fragments of nine residues.
2.4 | Calculating MHC binding predictions
Conserved CD8+ epitope predictions were made using the 
IEDB MHC I binding tool (http://www.iedb.org/mhci) with 
default IEDB recommended method and the IEDB HLA 
allele reference set. Epitopes with predicted affinities less 
than 100 nM (ANN IC50) were chosen for further analy-
sis. Conserved CD4+ epitope predictions were made using 
the IEDB MHC II binding tool (http://www.iedb.org/mhcii) 
with the “Human, HLA- DR” allele reference set selected. 
Epitopes with predicted affinities to HLA alleles of less than 
100 nM (SMM IC50) were retained for further analysis.
2.5 | Calculating epitope- predicted 
population coverage
The percentage of the population that possess at least one 
allele able to present at least one epitope within a group is 
termed the population protection coverage (PPC).[2] The se-
lected conserved CD8+ and CD4+ epitopes were entered 
into the IEDB population coverage tool (http://tools.iedb.org/
tools/population/iedb_input). The tool enables the PPC for a 
set of alleles to be calculated in 78 different populations.[19] 
Different combinations of epitopes were tested until a world 
PPC of >90% was achieved.
3 |  RESULTS
3.1 | Collection of MHC Class I and Class II 
epitopes and generation of a multiple sequence 
alignment and identification of conserved 
sequences in the dengue polyprotein
807 MHC Class I and 798 MHC Class II dengue virus 
epitopes were obtained from the IEDB. The dengue virus 
polyprotein genomic sequence [dengue virus type 2 (strain 
Thailand/NGS- C/1944) (DENV- 2)] was retrieved from 
UniProt and searched against the reference protein database 
using BLASTp. The top four scoring sequences (dengue 
virus serotype 2; dengue virus serotype 1; dengue virus se-
rotype 3; and dengue virus serotype 4) were used to create 
the MSA. Variability analysis of the MSA, using the protein 
variability server (PVS), identified 43 conserved fragments 
of nine or more residues within the dengue virus polyprotein.
3.2 | Identification of conserved CD8+ 
epitopes, predicting Class I binding and 
calculating population protection coverage
Epitopes overlapping conserved regions by at least 50% 
were selected, identifying 22 MHC Class I CD8+ epitopes. 
The IEDB MHC I binding prediction tool, using the human 
HLA allele reference set and a 2% cut- off, was used to pre-
dict epitope binding profiles. Epitopes which bound no MHC 
alleles were discarded. Where multiple epitopes had iden-
tical HLA binding profiles, a single representative epitope 
was chosen, selecting the affine epitope available: for ex-
ample, GPWHLGKLEL and GPWHLGKLEM both bind 
HLA- B*07:02; however, GPWHLGKLEM has a lower 
IC50 value. Only epitopes with an IC50 < 100 nM were ana-
lysed further. Together, epitopes were reduced from 22 to 
6: RAVHADMGYW, GPWHLGKLEM, GLYGNGVVTK, 
NMIIMDEAHF, KTWAYHGSY, and WAYHGSYEV (see 
Table 1).
The cumulative population protection coverage of the 
six selected MHC Class I epitopes was calculated using the 
IEDB PPC tool. The highest PPC achieved for an individual 
epitope was 30.92%, thus necessitating epitope combination. 
Using all six MHC Class I epitopes, a world population cov-
erage of 67.84% was achieved (see Table 2). The same com-
bination of epitopes has a population coverage of 31.76% 
in South America, 68.84% in South Asia, 57.60% in South- 
East Asia, 51.30% in Africa (50.32% in East Africa, 51.90% 
in West Africa, 43.72% in Central Africa, 53.03% in North 
Africa and 57.50% in South Africa) and 68.84% in South 
Asia.
3.3 | Identification of conserved MHC 
II epitopes, predicting MHC II binding and 
calculating population protection coverage
As mentioned above, epitopes overlapping conserved re-
gions by at least 50% were selected, identifying 55 MHC 
Class II CD4+ epitopes. A high sequence redundancy was 
seen between epitopes. Binding profiles were calculated, 
using a threshold of IC50 < 100 nM to define binding. 
Epitopes exhibited redundant HLA binding profiles. Where 
multiple epitopes had identical HLA binding profiles, a 
single representative epitope was chosen. For example, 
SLMYFHRRDLRLASN, WTLMYFHRRDLRLAA, WSLM 
YFHRRDLRLAA, LMYFHRRDLRLAANA, LMYFHRRD 
LRLASNA and WQLMYFHRRDLRLAA have bind-
ing profiles covered by WQLMYFHRRDLRLAA. Using 
this approach, 11 conserved CD4+ epitopes were selected: 
GVFHTMWHVTRGSVI, GKIVGLYGNGVVTTS, EIVD 
LMCHATFTMRL, AAIFMTATPPGSVEA, AAIFMTAT 
PPGTADA, GKTVWFVPSIKAGND, KFWNTTIA 
VSMANIF, RAIWYMWLGARYLEF, LAKAIF 
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KLTYQNKVV, VGTYGLNTFTNMEVQ and WTLMYFH 
RRDLRLAA (see Table S1).
The 11 MHC II epitopes had their PPC calculated. The 
highest world PPC for a single epitope was 23.19% for 
AAIFMTATPPGSVEA. Thus to reach a cumulative world 
PPC of >90%, a combination of epitopes is needed. A world 
PPC of 76.65% was achieved with a set of 11 MHC II epi-
topes (see Table S2). This combination PPC values are of: 
72.40% in East Asia, 71.79% in South Asia, 52.73% in South- 
East Asia, 54.97% in South America and 49.81% in Africa 
(53.62% in East Africa, 55.68% in West Africa, 44.68% in 
Central Africa, 68% in North Africa and 27.07% in South 
Africa).
3.4 | Using combinations of MHC Class 
I and MHC Class II epitopes to generate 
potential vaccines with >90% population 
protection coverage
A combination of 15 epitopes (six CD8+ and nine CD4+) 
generated a putative universal vaccine with a world popu-
lation coverage of 92.49% (see Table 3a). We also targeted 
Asia, South America and Africa, where dengue is endemic. 
The population coverage of epitopes from our potential 
universal vaccine was evaluated for East Asia. Selecting 
epitopes with a PPC value >10%, a maximum coverage 
of 85.83% was achieved. GPWHLGKLEM (PPC 9.44%) 
was added, increasing the cumulative PPC to 87.43% (see 
Table 3b). Likewise, a combination of five MHC Class I and 
nine MHC Class II epitopes achieved a combined PPC of 
90.23% for South Asia (see Table 3c). Attempts were also 
made to design putative vaccines with a population coverage 
of >90% targeting South America, West Africa, East Africa 
and Central Africa; however, such efforts proved futile. 
Selecting 15 conserved epitopes, we identified potential vac-
cines with a population coverage of 73.84% for East Africa, 
76.51 for West Africa and 66.5% for Central Africa. The 
T A B L E  2  Six selected conserved epitopes their binding profile 
and population protection coverage
Epitopes
MHC I- restricted 
allele(s)
Population 
coverage 
(world) (%)
RAVHADMGYW HLA- B*58:01, 
HLA- B*57:01
7.26
GPWHLGKLEM HLA- B*07:02 12.78
GLYGNGVVTK HLA- A*03:01, 
HLA- A*11:01
30.92
NMIIMDEAHF HLA- B*15:01 8.44
KTWAYHGSY HLA- A*30:02, 
HLA- A*32:01, 
HLA- B*57:01, 
HLA- A*01:01
26.65
WAYHGSYEV HLA- A*02:06, 
HLA- B*51:01
9.24
Epitope set All of the above 67.84
T A B L E  1  Binding profile of the 22 conserved MHC I epitopes. 
N/A means no MHC I- restricted alleles were found to present the 
epitope
Epitope sequence
MHC I- restricted 
alleles/IC50 (nM)
NRAVHADMGYWIESA N/A
KAVHADMGYW HLA-B*58:01/2.89 
HLA-B*57:01/19.89
RAVHADMGYW HLA-B*58:01/2.86 
HLA-B*57:01/21.14 
HLA- B*53:01/257.44
GPWHLGKLEL HLA-B*07:02/9.11
GPWHLGKLEM HLA-B*07:02/4.7
GLYGNGVVTK HLA-A*03:01/24.91 
HLA-A*11:01/42.32
IMDEAHFTDPASIARRG N/A
NMIIMDEAHF HLA-B*15:01/41.74 
HLA- A*23:01 101.08
LIVMDEAHFTDPSSVAA N/A
NYNLIIMDEAHFTDPA N/A
NYNLIIMDEAHFTDPASI N/A
NYNMIIMDEAHFTDPA N/A
MGEAAAIFMTATPPGSV N/A
VEMGEAAAIFMTATPPG N/A
LMRRGDLPVWLAYRV N/A
MRRGDLPVWL N/A
DLMRRGDLPV HLA- A*02:01/200.17 
HLA- A*02:03/1162.7
WHYDEDNPYKTWAYHGSYEV N/A
KTWAYHGSYETKQTG N/A
KTWAYHGSY HLA-A*30:02/3.14 
HLA-A*32:01/20.9 
HLA-B*57:01/27.08 
HLA-A*01:01/60.47 
HLA- B*15:01/153.39 
HLA- A*03:01/232.14 
HLA- B*58:01/255.91 
HLA- A*11:01/295.76
WAYHGSYET HLA- B*35:01/3038.67
WAYHGSYEV HLA-A*02:06/42.32 
HLA-B*51:01/77.05 
HLA- A*68:02/107.43 
HLA- B*35:01/9748.16
The HLA alleles and IC50 values in bold font were under the threshold of 100 nM 
required and were further analysed.
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T A B L E  3  (A) The set of 15 epitopes (six MHC Class I and nine MHC Class II) and their HLA binding profiles used to generate a universal 
vaccine with a world population coverage of 92.49%. (B) The set of 11 epitopes (four MHC I and seven MHC II) and their MHC- restricted alleles 
that have a cumulative population coverage of 87.43% in East Asia. (C) The set of 14 epitopes (five MHC I and nine MHC II) and their HLA 
binding profiles, which have a cumulative population coverage of 90.23% in South Asia and 82.59% in Asia (88.97% in East Asia, 84.25% in 
Northeast Asia, 90.23% in South Asia, 76.67% in South- East Asia and 72.86% in Southwest Asia) (Bui et al., 2006)
(A)
Epitope sequence MHC- restricted epitopes
Population coverage (world) 
(%)
RAVHADMGYW HLA- A*30:02, HLA- A*32:01, HLA- B*57:01, HLA- A*01:01 7.26
GPWHLGKLEM HLA- B*07:02 12.78
GLYGNGVVTK HLA- A*03:01, HLA- A*11:01 30.92
NMIIMDEAHF HLA- B*15:01 8.44
KTWAYHGSY HLA- A*30:02, HLA- A*32:01, HLA- B*57:01, HLA- A*01:01 26.65
WAYHGSYEV HLA- A*02:06, HLA- B*51:01 9.24
LAKAIFKLTYQNKVV HLA- DRB1*07:01, HLA- DRB3*02:02, HLA- DRB5*01:01, 
HLA- DPA1*02:01/DPB1*01:01, HLA- DPA1*02:01/DPB1*14:01
18.23
GKIVGLYGNGVVTTS HLA- DRB1*15:01, HLA- DQA1*05:01/DQB1*03:01 18.41
AAIFMTATPPGSVEA HLA- DRB1*04:01, HLA- DRB1*11:01, HLA- DRB3*02:02, 
HLA- DRB1*08:02
23.19
AAIFMTATPPGTADA HLA- DRB1*04:01, HLA- DRB1*09:01 17.24
GKTVWFVPSIKAGND HLA- DRB1*08:02, HLA- DRB1*11:01 12.74
KFWNTTIAVSMANIF HLA- DRB1*07:01, HLA- DQA1*01:02/DQB1*06:02, 
HLA- DRB1*08:02
20.33
RAIWYMWLGARYLEF HLA- DPA1*01:03/DPB1*02:01, HLA- DRB1*01:01, HLA- 
DRB5*01:01, HLA- DPA1*02:01/DPB1*14:01, HLA- DPA1*01/
DPB1*04:01
11.53
VGTYGLNTFTNMEVQ HLA- DRB1*04:05 3.02
WTLMYFHRRDLRLAA HLA- DRB3*01:01, HLA- DRB3*02:02, HLA- DRB1*03:01 17.84
Epitope set All of the above 92.49
(B)
Epitope Sequence MHC allele(s)
Population coverage (East 
Asia) (%)
GLYGNGVVTK HLA- A*03:01, HLA- A*11:01 17.76
GPWHLGKLEM HLA- B*07:02 9.44
NMIIMDEAHF HLA- B*15:01 17.64
WAYHGSYEV HLA- A*02:06, HLA- B*51:01 28.09
GKIVGLYGNGVVTTS HLA- DRB1*15:01, HLA- DQA1*05:01/DQB1*03:01 12.18
AAIFMTATPPGSVEA HLA- DRB1*04:01, HLA- DRB1*11:01, HLA- DRB3*02:02, 
HLA- DRB1*08:02
16.18
AAIFMTATPPGTADA HLA- DRB1*04:01, HLA- DRB1*09:01 23.96
GKTVWFVPSIKAGND HLA- DRB1*08:02, HLA- DRB1*11:01 13.19
KFWNTTIAVSMANIF HLA- DRB1*07:01, HLA- DQA1*01:02/DQB1*06:02, 
HLA- DRB1*08:02
13.88
RAIWYMWLGARYLEF HLA- DPA1*01:03/DPB1*02:01, HLA- DRB1*01:01, HLA- 
DRB5*01:01, HLA- DPA1*02:01/DPB1*14:01, HLA- DPA1*01/
DPB1*04:01
10.21
VGTYGLNTFTNMEVQ HLA- DRB1*04:05 19.23
Epitope set All of the above 87.43
(Continues)
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same 15 epitope combination had a population coverage of 
68.81% for South America and 80.80% for Brazil.
4 |  DISCUSSION
We designed several putative epitope ensemble vaccines 
using an optimized selection of conserved dengue epitopes 
of verified immunogenicity. From the 807 MHC Class I 
epitopes and 798 MHC Class II epitopes originally found in 
IEDB, a final combination of six conserved CD8+ and nine 
conserved CD4+ epitopes had a cumulative world PPC value 
of 92.49%. Compared to the universal influenza vaccine de-
signed by Sheikh et al.,[2] our potential dengue vaccine had 
an extra epitope. Attempts to design putative vaccines target-
ing endemic regions only yielded a PPC value of 76.67%. 
However, a combination of four CD8+ and seven CD4+ 
epitopes had a population coverage of 87.43% across East 
Asia. For South Asia, 4 CD8+ and 11 CD4+ epitopes had a 
cumulative PPC value of 90.23%.
Currently CYD- TDV, manufactured under the name 
“Dengvaxia®” by Sanofi Pasteur, is the only vaccine to pro-
vide any prophylaxis against dengue virus infection. CYD- 
TDV is a live, attenuated tetravalent chimeric vaccine. Overall 
vaccine efficacy is low and varies significantly between 
geographical locations and between virus serotypes.[12] How 
this vaccine protects from the effect of secondary infection by 
a different genotype is unclear. A better approach might be to 
elicit an immune response against conserved T- cell epitopes. 
An effective vaccine against dengue should ideally have a 
much higher efficacy than CYD- TDV, especially in endemic 
regions. Our putative epitope- based vaccine comprises epi-
topes conserved between all four dengue virus serotypes and 
hopefully elicits a controlled immune response providing 
future homotypic and heterotypic immunity to vaccinated 
population. The estimated PPC values of several of our po-
tential vaccines, such as those targeting South- East Asia and 
South America, exceed the equivalent measured efficacy of 
CYD- TDV.
Similar to CYD- TDV, “DENVax” is unlikely to provide 
heterotypic immunity, due to DENV- 4 having a low seropos-
itivity. A putative vaccine comprising epitopes conserved in 
all four dengue serotypes could be the best route to hetero-
typic immunity, without causing danger to the individual. 
Current vaccine trials and vaccination programmes are not 
giving the expected protection to dengue infection. In par-
ticular, the Philippines has stopped dengue vaccination and 
marketing of Sanofi Pasteur’s Dengvaxia, the first licensed 
dengue vaccine. Postvaccination testing indicated that 
Dengvaxia increases the risk of severe dengue in those not 
(C)
Epitope sequence MHC binding allele(s)
Population coverage (South 
Asia) (%)
GLYGNGVVTK HLA- A*03:01, HLA- A*11:01 33.60
GPWHLGKLEM HLA- B*07:02 2.74
NMIIMDEAHF HLA- B*15:01 4.29
WAYHGSYEV HLA- A*02:06, HLA- B*51:01 15.19
GKIVGLYGNGVVTTS HLA- DRB1*15:01, HLA- DQA1*05:01/DQB1*03:01 16.45
AAIFMTATPPGSVEA HLA- DRB1*04:01, HLA- DRB1*11:01, HLA- DRB3*02:02, 
HLA- DRB1*08:02
15.28
AAIFMTATPPGTADA HLA- DRB1*04:01, HLA- DRB1*09:01 4.93
GKTVWFVPSIKAGND HLA- DRB1*08:02, HLA- DRB1*11:01 12.70
KFWNTTIAVSMANIF HLA- DRB1*07:01, HLA- DQA1*01:02/DQB1*06:02, 
HLA- DRB1*08:02
29.09
RAIWYMWLGARYLEF HLA- DPA1*01:03/DPB1*02:01, HLA- DRB1*01:01, HLA- 
DRB5*01:01, HLA- DPA1*02:01/DPB1*14:01, HLA- DPA1*01/
DPB1*04:01
9.25
VGTYGLNTFTNMEVQ HLA- DRB1*04:05 1.01
RAVHADMGYW HLA- A*30:02, HLA- A*32:01, HLA- B*57:01, HLA- A*01:01 26.42
LAKAIFKLTYQNKVV HLA- DRB1*07:01, HLA- DRB3*02:02, HLA- DRB5*01:01, 
HLA- DPA1*02:01/DPB1*01:01, HLA- DPA1*02:01/DPB1*14:01
28.49
WTLMYFHRRDLRLAA HLA- DRB3*01:01, HLA- DRB3*02:02, HLA- DRB1*03:01 16.37
Set of epitopes All of the above 90.23
T A B L E  3  (Continued)
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previously exposed to the virus. The molecular mechanism 
underlying this phenomenon remains unclear, but may act by 
overpriming the innate immune response. Both “DENVax” 
and “Dengvaxia®” are chimeric subunit vaccines, containing 
just the premembrane and membrane proteins from the dif-
ferent serotypes. The conserved epitopes we identified came 
from nonstructural proteins and the polyprotein. A combina-
tion of 15 epitopes, with a population coverage of 92.9%, if 
maintained in vivo, would likely provide effective protection 
against Dengue. The overpriming is highly unlikely to be an 
issue with our epitope- based approach, which targets recog-
nition specifically rather than through a strategy based on 
subunit vaccines, with their much enhanced risk of inappro-
priate immune reactions.
Multiple epitope combinations within each designed 
potential vaccine increases the chances of cross- protection 
among all four dengue serotypes. Vaccines, as supramolecu-
lar entities, work primarily by potentiating the host immune 
system. Vaccines protect by inducing cellular or molecular 
effector mechanisms able rapidly to inactivate toxic compo-
nents or control replicating pathogens. In history, vaccines 
have induced antibodies produced by B cells capable of 
binding specifically to a toxin or a pathogen. More recent, 
as diseases amenable to antibody- mediated vaccines have 
become rarer, attention has turned to cytotoxic CD8+ and 
CD4+ T cells as alternative effectors. CD8+ T cells limit 
the proliferation of infectious micro- organisms by recogniz-
ing and killing infected cells or producing specific antiviral 
cytokines, while CD4+ T- helper (Th) lymphocytes limit the 
protection by secreting cytokine and help support the gener-
ation of B and CD8+ T- cell responses. Effector CD4+ Th 
cells can be subdivided into T- helper (Th1) or T- helper 2 
(Th2) subsets depending on their main cytokine production 
(interferon- γ or interleukin [IL]- 4). On this basis, an epitope 
ensemble vaccine, derived solely from T- cell epitopes, bene-
fits from inclusion of both CD8+ and CD4+ broad coverage 
epitopes. Class I peptide binding can be predicted, with high 
accuracy being achieved.[20,21] It is likely that the epitope- 
MHC I IC50 predictions in Results section are accurate. In 
the case of Class II binding predictions, the same accuracy is 
rarely achieved due to MHC II molecules having open bind-
ing grooves.[22] From the six MHC I epitopes selected in the 
potential universal vaccine, only two of the epitopes were 
9- mers. However, our previous work only selected MHC I 
epitopes that were nine residues long.[1,2] Reche et al[23] state 
that most peptides presented in peptide- MHC- TCR interac-
tion are 9- mers, although epitopes between 8 and 16 resi-
dues in length are also known to be presented by MHC I, but 
to a lesser extent.
Epitopes require delivery with the addition of adjuvants—
which can be broadly defined as substance which when added 
to a molecule enhances its immunogenicity.[24] An exam-
ple of this is the tetravalent vaccine containing monovalent 
DNA vaccine against DENV, which has undergone an ini-
tial Phase I clinical trial. It is combined with equal amounts 
of Vaxfectin® (Vical Inc.) to enhance its immunogenicity. 
Schubert and Kohlbacher assert that the use of string- of- bead 
polypeptides, employing spacers between epitopes, increases 
the prediction of correct in vivo cleavage epitope recovery 
rate by fivefold.[25] Using this method of delivery combined 
with adjuvant could enable the peptides in our potential vac-
cine to successfully provide immune protection against den-
gue infection.
The generation of successful peptide vaccines using in 
silico methods would provide a pathway to safer vaccines. 
Development of the vaccine itself would likely take less 
time compared to other vaccine types, and come at a lower 
cost, while being potentially more effective. Exploitation of 
peptide vaccines would especially benefit regions with low- 
quality health care, such as South- East Asia and Africa, as 
they should not necessitate such extensive cold chains. There 
remains the rare possibility that a live vaccine could revert to 
a disease- inducing form, as occurs with polio. An epitope- 
based vaccine would not have such disadvantages. Successful 
development of an epitope- based universal vaccine along 
with the other vaccines proposed—assuming that they re-
tain efficacy in vivo—has the potential both to save lives and 
to reduce the economic burden of dengue virus. Currently, 
our putative vaccine contains no B- cell component. Even 
adequate prediction of B- cell epitopes lies well beyond the 
capacity of current immunoinformatics. However, immune 
responses against conserved epitopes will likely enhance 
antibody- mediated responses.
In this work, he has shown clearly and explicitly how 
the process of molecular design can be used to design vac-
cines in exactly the same way as it is used in other areas 
of synthetic chemistry, drug design, synthetic systems bi-
ology or translational biomedicine. Design- by- selection, 
as we use it here, is the hierarchical preprocessing of 
extant data, allowing the effective combination and ex-
ploitation of computational prediction and experimentally 
validated prior knowledge.[1–3] Other powerful methods 
and approaches are available: The main competitor to our 
approach uses a large number of different immunoinfor-
matics and bioinformatics methods to predict from the 
virtual proteome a set of putative epitopes lacking inde-
pendent experimental verification and then seeks to val-
idate these using more speculative approaches, such as 
docking and molecular dynamics, or, more infrequently, 
using experimental post hoc validation.[26] Our strategy 
by contrast allows us to reduce a vast search space of 
potential vaccine ensembles to a handful of viable, pre-
verified candidate solutions. As each is built from preval-
idated epitopes, each of our vaccine ensemble candidates 
is likely to be widely immunogenic and should be priori-
tized for in vivo testing.
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